Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Marinus Pharmaceuticals Inc Market Cap
The Marinus Pharmaceuticals Inc (MRNS) share price is expected to increase by 381.33% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered MRNS. Price targets range from $2 at the low end to $13 at the high end. The current analyst consensus for MRNS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
MRNS is a stock in Health Care which has been forecasted to be worth $7.22 as an average. On the higher end, the forecast price is $13 USD by Michael Higgins from Ladenburg Thalmann and on the lower end MRNS is forecasted to be $2 by Brian Skorney from Baird.
These are the latest 20 analyst ratings of MRNS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Michael Higgins Ladenburg Thalmann | Neutral | Downgrade | Aug 14, 2024 | |
| Douglas Tsao HC Wainwright & Co. | Buy | $11 | Reiterates | Aug 14, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $11 | Reiterates | Jun 18, 2024 |
| Joon Lee Truist Securities | Buy | $10 | Maintains | Jun 18, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $11 | Reiterates | May 9, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $11 | Maintains | May 7, 2024 |
| Joon Lee Truist Securities | Buy | $10 | Maintains | Apr 17, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $27 | Reiterates | Apr 16, 2024 |
| Brian Skorney Baird | Neutral | $2 | Downgrade | Apr 16, 2024 |
| Brian Abrahams RBC Capital | Sector Perform | $3 | Downgrade | Apr 15, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $28 | Reiterates | Apr 10, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $27 | Reiterates | Mar 26, 2024 |
| Jay Olson Oppenheimer | Perform | $9 | Maintains | Mar 7, 2024 |
| Brian Abrahams RBC Capital | Outperform | $24 | Reiterates | Mar 6, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $27 | Reiterates | Mar 6, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $27 | Reiterates | Dec 5, 2023 |
| Joon Lee Truist Securities | Buy | $25 | Maintains | Nov 8, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $28 | Reiterates | Sep 21, 2023 |
| Brian Abrahams RBC Capital | Outperform | $21 | Maintains | Sep 20, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $27 | Reiterates | Sep 20, 2023 |
When did it IPO
2014
Staff Count
165
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Scott N. Braunstein M.D.
Market Cap
$81.0M
In 2023, MRNS generated $31.0M in revenue, which was a increase of 21.63% from the previous year. This can be seen as a signal that MRNS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
